Christoph Droogan, DO
Advanced Heart Failure and Transplant Cardiology · Wynnewood, PANPI 1174528129
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $264,727 of the $291,400 with a category attached, or 90.8%. 24 manufacturers reported payments, led by Lilly USA, LLC at 39.7% of the total. Reporting peaked in 2019 at $73,300 and has fallen 82.8% since, to $12,597 in 2025. Among advanced heart failure and transplant cardiology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 381 payments — averaging $764.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$116K
- Boehringer Ingelheim$112K
- Merck$23K
- Novartis$21K
- Daxor Corporation$7K
- Bayer$5K
- plus $7K from 18 others
Across 35 payments — averaging $1305.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$44K
- Janssen Research & Development, LLC$1K
What the payments were for
- Consulting fees$12,4454%
- Speaking & faculty fees$264,72791%
- Travel & lodging$5,1332%
- Food & beverage$9,0953%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 133 | $115,808 |
| Boehringer Ingelheim | 128 | $112,441 |
| Merck | 25 | $23,472 |
| Novartis | 20 | $20,765 |
| Daxor Corporation | 6 | $6,965 |
| Bayer | 6 | $5,295 |
| Biotronik Inc. | 2 | $1,533 |
| Abbott | 12 | $1,228 |
| Boston Scientific | 11 | $1,188 |
| Edwards Lifesciences | 2 | $1,012 |
| Abiomed | 6 | $468 |
| E.r. Squibb & Sons, L.L.C. | 6 | $290 |
| Actelion Pharmaceuticals US, Inc. | 6 | $156 |
| Impulse Dynamics (USA) Inc. | 1 | $143 |
| La Jolla Pharmaceutical Company | 1 | $139 |
| ZOLL Respicardia, Inc. | 1 | $132 |
| AstraZeneca | 5 | $129 |
| AbbVie | 3 | $100 |
| Pfizer | 2 | $41 |
| Alnylam Pharmaceuticals Inc. | 1 | $25 |
| Novo Nordisk | 1 | $24 |
| United Therapeutics Corporation | 1 | $17 |
| Scpharmaceuticals Inc. | 1 | $16 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$174,252
- TRULICITY$47,500
- VERQUVO$39,559
- ENTRESTO$20,374
- BVA-100$6,933
- Kerendia$5,077
- Watchman$910
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$868
- OPTIMIZER$286
- Impella$271
- CARDIOMEMS$169
- GIAPREZA$139
- GENERAL - THERAPIES$138
- remede System$132
How this compares
$291,400 in reported general payments places this provider in the 95th percentile of 96 advanced heart failure and transplant cardiology providers in Pennsylvania.
See all advanced heart failure and transplant cardiology providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 198 | $236,770 |
| JardianceEmpagliflozin | 91 | $108,095 |
| EntrestoSacubitril/Valsartan | 69 | $85,869 |
| XareltoRivaroxaban | 49 | $68,088 |
| Atorvastatin Calcium | 561 | $8,819 |
| Metoprolol Succinate | 306 | $6,106 |
| Rosuvastatin Calcium | 234 | $4,635 |
| Ezetimibe | 177 | $4,632 |
| Valsartan | 69 | $2,864 |
| Carvedilol | 197 | $2,754 |
| ClopidogrelClopidogrel Bisulfate | 127 | $2,149 |
| Amlodipine Besylate | 301 | $2,115 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 24 | $1,874 |
| Losartan Potassium | 137 | $1,828 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 11 | $1,766 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $41 | $236,770198 claims |
| Boehringer IngelheimJardiance | $112,441 | $108,09591 claims |
| NovartisEntresto | $20,765 | $85,86969 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 96 advanced heart failure and transplant cardiology providers in Pennsylvania.
Other advanced heart failure and transplant cardiology in Wynnewood
- Steven DomskyWynnewood$151K
- Anjali VaidyaPhiladelphia$762K
- Brendan CarryDanville$424K
- Andrew PogozelskiPittsburgh$401K
- Jesus RamePhiladelphia$336K
- Ileana PinaPhiladelphia$284K
- Jeremy MazurekPhiladelphia$142K
- Lee GoldbergPhiladelphia$130K
- Anjali OwensPhiladelphia$109K
- Behnam BozorgniaPhiladelphia$107K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.